Transaction DateRecipientSharesTypePriceValue
15th September 2020Scott B. Ullem33,150Open or private sale$83.43$2,765,747.59
15th September 2020Scott B. Ullem33,150Exercise of derivative$21.76$721,344.00
14th September 2020Scott B. Ullem26,700Exercise of derivative$13.98$373,266.00
14th September 2020Scott B. Ullem26,700Open or private sale$82.21$2,194,908.21
11th September 2020Huimin Wang310Open or private sale$82.97$25,720.39
11th September 2020Huimin Wang11,339Open or private sale$82.43$934,625.01
11th September 2020Huimin Wang81Open or private sale$83.00$6,723.00
11th September 2020Donald E Jr Bobo876Open or private sale$82.90$72,623.99
11th September 2020Donald E Jr Bobo13,074Exercise of derivative$13.98$182,774.52
11th September 2020Huimin Wang11,649Exercise of derivative$13.98$162,853.02
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.


Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.


Ticker: EW
Sector: Healthcare
Industry: Medical Devices
SEC Central Index Key (CIK): 1099800
Employees: 13900
Exchange: New York Stock Exchange
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $904 M (-23%)
Inventory, Net: $735 M (0%)
Other Assets, Current: $166 M (-1%)
Assets, Current: $3 B (-9%)
Property, Plant and Equipment, Net: $1 B (12%)
Other Assets, Noncurrent: $154 M (51%)
Assets: $6 B (0%)
Accounts Payable, Current: $153 M (-14%)
Liabilities, Current: $873 M (-3%)
Long-term Debt, Excluding Current Maturities: $595 M (0%)
Other Liabilities, Noncurrent: $466 M (0%)
Common Stock, Value, Issued: $634 M (190%)
Common Stock, Shares, Issued: $634 M (190%)
Additional Paid in Capital, Common Stock: $1 B (-18%)
Retained Earnings (Accumulated Deficit): $4 B (5%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $146 M (-6%)
Treasury Stock, Value: $19 Th (48%)
Treasury Stock, Shares: $121 M (34%)
Stockholders' Equity (Parent): $4 B (0%)
Liabilities and Equity: $6 B (0%)
Revenue: $925 M (0%)
Cost of Revenue: $238 M (0%)
Gross Margin: $687 M (-55%)
Research and Development: $182 M (-50%)
Operating Income/Loss: $170 M (0%)
Income before taxes: $168 M (0%)
Provision for income taxes: $46 M (509%)
EPS (basic): $0.2 (0%)
EPS (diluted): $0.2 (0%)